Lipid Or Cholesterol Affecting (e.g., Dyslipidemia, Etc.) Patents (Class 514/7.4)
-
Publication number: 20130344173Abstract: In certain embodiments transgenic plants (e.g., transgenic tomatoes) are provided that comprise cells that express a peptide one or more domains of which comprise the amino acid sequence of an apolipoprotein or apolipoprotein mimetic peptide where the peptide has biological activity (e.g., lowers SAA, and/or increases paroxonase activity, and/or improves HDL inflammatory index, etc.) when the plant and/or the peptide is fed to a mammal.Type: ApplicationFiled: March 7, 2013Publication date: December 26, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: ALAN M. FOGELMAN, SRINIVASA T. REDDY, MOHAMAD NAVAB
-
Patent number: 8613963Abstract: A nutritional supplement specifically designed to lower cholesterol that addresses multiple mechanisms including hepatic synthesis and release, intestinal absorption of cholesterol, while, at the same time, including ingredients that mitigate the side effects of the constituents and increase their efficacy by affecting emotional factors that influence compliance such as a sense of well-being and euphoria on the one hand, or an increased overall metabolism and desire for the product stemming from its coloration on the other hand. The nutritional supplement can be prepared as a powder that can be added to a food item by a human subject, a concentrate that can be mixed with water or another beverage, or incorporated into a baked good for ingestion by the human subject.Type: GrantFiled: August 24, 2010Date of Patent: December 24, 2013Assignee: Healthy Drink Discoveries IncorporatedInventor: Mitchell Karl
-
Publication number: 20130331324Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of dyslipidemia and associated complications such as alcoholic and non-alcoholic fatty liver disease.Type: ApplicationFiled: August 21, 2013Publication date: December 12, 2013Applicant: Ipsen Pharma, S. A. S.Inventors: Heather A. HALEM, Michael DeWitt CULLER
-
Publication number: 20130324460Abstract: This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.Type: ApplicationFiled: August 13, 2013Publication date: December 5, 2013Applicant: Eli Lilly and CompanyInventors: Craig Duane DICKINSON, David Albert DRIVER, Ryan James DARLING, Malgorzata Donata GONCIARZ, Radmila MICANOVIC
-
Publication number: 20130316941Abstract: The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and/or for the treatment of diabetes. The compounds may mediate their effect, inter alia, by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: December 19, 2012Publication date: November 28, 2013Applicants: Boehringer Ingelheim International GmbH, Zealand Pharma A/SInventors: Dieter Wolfgang Hamprecht, Jakob Lind Tolborg, Ditte Riber
-
Publication number: 20130310315Abstract: The present invention relates to a method for assessing a subject's risk of having a cardiovascular disease comprising the step of measuring the level of IF1 in a body fluid sample obtained from said subject wherein the level of EF1 is negatively correlated with the risk of said subject of having cardiovascular disease.Type: ApplicationFiled: January 25, 2012Publication date: November 21, 2013Applicants: Institut National de la Sante et de la Recherche Medicale(Inserm), CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Laurent Martinez, Bertrand Perret, Annelise Genoux
-
Publication number: 20130302339Abstract: The present invention relates to a composition useful for the diagnosis and therapy of diseases associated with aberrant expression of the gene encoding the receptor Kremen 1 and/or Kremen 2 e.g. tumors or diseases of the kidneys, bones and eyes, lipid and glucose metabolism and obesity. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Kremen 1 and/or Kremen 2 or (b) the activity of the Kremen 1 and/or Kremen 2 receptor.Type: ApplicationFiled: June 22, 2012Publication date: November 14, 2013Inventors: Christof Niehrs, Bingyu Mao
-
Publication number: 20130296226Abstract: Embodiments described herein are directed to methods for the treatment and control of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae that are associated with these diseases, including atherosclerosis and non-insulin dependent diabetes. In addition, embodiments are directed to methods of treating coronary heart disease and metabolic syndrome. Embodiments are also directed to neurotensin analogs. In embodiments, the neurotensin analogs may be capable of binding to neurotensin receptors and, upon binding, may modulate the levels of lipids in subjects.Type: ApplicationFiled: June 29, 2013Publication date: November 7, 2013Inventors: Gautam S. GHATNEKAR, Justin BROWER
-
Publication number: 20130295042Abstract: This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of eye disease and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route or via intraocular injection.Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Inventors: Gattadahalli M. Anantharamaiah, Martin Rudolph, Alan M. Fogelman, Mohamad Navab
-
Patent number: 8575091Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.Type: GrantFiled: June 28, 2013Date of Patent: November 5, 2013Assignee: Novo Nordisk A/SInventors: Kirsten Dahl, Lauge Schaeffer, Thomas Kruse
-
Patent number: 8574619Abstract: A method of reducing the cholesterol level of a subject by administering to that subject quercetin, vitamin C, vitamin B3, and statin.Type: GrantFiled: September 5, 2008Date of Patent: November 5, 2013Assignee: Quercegen Pharmaceuticals, LLCInventor: Thomas Christian Lines
-
Publication number: 20130288961Abstract: Methods for treating fatty liver disease, e.g., hepatic steatosis, using peptide fragments of the C-terminal end of glucagon-like peptide-1 (GLP-1), e.g., GLP-1(28-36).Type: ApplicationFiled: November 2, 2011Publication date: October 31, 2013Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Joel F. Habener, Eva Tomas-Falco
-
Patent number: 8569455Abstract: A truncated form of ?? chain (e??), the soybean 7S globulin, active in controlling the cholesterol and triglyceride homeostasis in in vitro and in vivo models, was cloned and expressed in the yeast Pichia pastoris. The recombinant polypeptide spanned 142 amino acid residues from the N-terminal side and included the N-terminal extension region of the soybean alpha? subunit. The e?? polypeptide was purified by conventional biochemical techniques and its potential to modulate the activity of the LDL-receptor was evaluated in a human hepatoma cell line (Hep G2) by monitoring the uptake and degradation of labeled LDL.Type: GrantFiled: June 16, 2010Date of Patent: October 29, 2013Assignee: Indena S.p.A.Inventors: Paolo Morazzoni, Antonella Riva, Cesare Ponzone, Davide Berlanda, Marcello Duranti, Alessandro Consonni
-
Publication number: 20130281358Abstract: The invention provides a peptide comprising or consisting of SEQ ID NO: 1 and variants thereof, particularly comprising of consisting of the sequence FTY, nucleic acids encoding said peptides and pharmaceutical and nutraceutical compositions comprising said peptide(s) and/or nucleic acids. Also provided is the use of such a peptide in therapy and in vitro methods of ACE-inhibition.Type: ApplicationFiled: July 13, 2011Publication date: October 24, 2013Applicant: Marealis ASInventor: Jaran Rauo
-
Publication number: 20130281367Abstract: An agent for suppressing elevation of blood GIP level, an agent for suppressing elevation of blood insulin level, an agent for lowering blood triglyceride level after meal ingestion and an agent for suppressing elevation of blood glucose level, these agents containing potassium polyglutamates as active ingredients.Type: ApplicationFiled: December 20, 2011Publication date: October 24, 2013Applicant: KAO CORPORATIONInventors: Kotomi Ishimaru, Kazuhisa Sawada, Noriko Osaki
-
Patent number: 8557767Abstract: The present invention provides novel synthetic apolipoprotein E (ApoE)-mimicking peptides wherein the receptor binding domain of apolipoprotein E is covalently linked to 18A, the well characterized lipid-associating model class A amphipathic helical peptide, or a modified version thereof. Such peptides enhance low density lipoprotein (LDL) and very low density lipoprotein (VLDL) binding to and degradation by fibroblast or HepG2 cells. Also provided are possible applications of the synthetic peptides in lowering human plasma LDL/VLDL cholesterol levels, thus inhibiting atherosclerosis. The present invention also relates to synthetic peptides that can improve HDL function and/or exert anti-inflammatory properties.Type: GrantFiled: August 27, 2008Date of Patent: October 15, 2013Assignee: UAB Research FoundationInventors: Gattadahalli M. Anantharamaiah, David W. Garber, Geeta Datta, Sheila P. Handattu, Vinod K. Mishra
-
Publication number: 20130261054Abstract: The present disclosure provides a method for treating and/or preventing nephrotic syndrome, such as but not limited to MCD and MN, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject.Type: ApplicationFiled: February 2, 2012Publication date: October 3, 2013Applicant: THE UAB RESEARCH FOUNDATIONInventor: Sumant S. CHUGH
-
Publication number: 20130252879Abstract: Provided is a rapamycin formulation using a recombinant high-density lipoprotein including apolipoprotein mutant, the rapamycin formulation in which solubility of rapamycin and medical use, such as aging suppression and arteriosclerosis suppression, are improved by using recombinant high-density lipoprotein including apolipoprotein A-I and its mutant V156K.Type: ApplicationFiled: October 25, 2011Publication date: September 26, 2013Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YEUNGNAM UNIVERSITYInventor: Kyung-Hyun Cho
-
Publication number: 20130252884Abstract: Novel analogues of Fibroblast Growth Factor 21 (FGF21), derivatives thereof having a modifying moiety covalently attached thereto, and pharmaceutical use of these analogues and derivatives, in particular, for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD) are described.Type: ApplicationFiled: June 6, 2011Publication date: September 26, 2013Applicant: NOVO NORDISK A/SInventors: Patrick William Garibay, Helle Woeldike, Xujia Zhang, Henning Thoegersen, Peter Kresten Nielsen, Birgitte Andersen, Jishu Wang, Kristian Sass Bak-Jensen, Tina Moeller Tagmose
-
Publication number: 20130252887Abstract: The invention features compositions and methods of using a dimeric inhibitor, e.g., A1-A1, to selectively target ?2GPI in ?2GPI/antibody complexes. The compositions can be administered to subjects (e.g., a mammal, such as a human) having or likely to develop APS, or one or more symptoms of APS, in order to treat or inhibit the disease or treat or reduce its symptoms. The inhibitors of the invention include two ligand-binding A1 modules, e.g., from ApoER2, connected by a flexible linker.Type: ApplicationFiled: October 31, 2011Publication date: September 26, 2013Inventor: Natalia Beglova
-
Patent number: 8541236Abstract: In one aspect, the present invention provides isolated oxidation resistant mutant apoA-I polypeptides comprising an amino acid sequence substantially homologous to SEQ ID NO:4, the mutant apoA-I polypeptide comprising a combination of: (1) a conservative amino acid substitution at residue Tyr192; and (2) at least one conservative amino acid substitution at residue Met86, Met112, or Met148, wherein the mutant apoA-I polypeptide is resistant to modification by an oxidizing agent. In another aspect, the invention provides a method of promoting cholesterol efflux activity in a mammalian subject in need thereof, the method comprising the step of administering an effective amount of an oxidation resistant apoA-I agonist to the subject to promote cholesterol efflux.Type: GrantFiled: December 6, 2007Date of Patent: September 24, 2013Assignees: University of Washington, The Children's Hospital & Research Center At OaklandInventors: Jay W. Heinecke, John F. Oram, Michael N. Oda
-
Patent number: 8536117Abstract: A method for the treatment of cardiovascular disease or disorder in a subject in need thereof, the method comprising the steps of administering an ApoA1 mimetic that is capable of promoting cholesterol efflux from lipid loaded cells in the subject, wherein the ApoA1 mimetic has an amino acid sequence that includes at least a portion of the amino acid sequence of ApoA1 or a mimetic of ApoA1 that contains at least one tryptophan, at least one tryptophan from the ApoA1 or mimetic of the ApoA1 being substituted with an oxidant resistant amino acid in the amino acid sequence of the ApoA1 mimetic.Type: GrantFiled: February 14, 2012Date of Patent: September 17, 2013Assignee: The Cleveland Clinic FoundationInventors: Jonathan D. Smith, Stanley L. Hazen
-
Publication number: 20130237473Abstract: The invention relates to melanocortin receptor-specific cyclic peptides of Formula (I) or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4a, R4b, R4c, R5, x and y are as defined in the specification. These compounds are particularly useful in the treatments of energy homeostasis and metabolism related (e.g. diabetes), food intake related and/or energy balance and body weight related diseases, disorders and/or conditions, including obesity, overweight and diseases, disorders and/or conditions associated with obesity and/or overweight, such as type 2 diabetes and metabolic syndrome.Type: ApplicationFiled: May 3, 2013Publication date: September 12, 2013Applicant: AstraZeneca ABInventors: John H. Dodd, Yi-Qun Shi, Wei Yang
-
Patent number: 8530414Abstract: The present invention relates to antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9), or antigen-binding fragments thereof, compositions comprising such PCSK9 antibodies or antigen-binding fragments, and methods of using the same for the treatment of hyperlipidemia or hypercholesterolemia.Type: GrantFiled: September 12, 2012Date of Patent: September 10, 2013Assignee: Eli Lilly and CompanyInventors: Julian Davies, Ryan James Darling, Barrett Allan
-
Publication number: 20130231273Abstract: Herein is reported a shortened tetranectin-apolipoprotein A-I fusion protein and a lipid particle comprising the shortened tetranectin-apolipoprotein A-I fusion protein as well as uses thereof.Type: ApplicationFiled: August 22, 2012Publication date: September 5, 2013Applicant: Hoffmann-La Roche Inc.Inventors: Martin Bader, Roberto Falkenstein, Christian Schantz
-
Publication number: 20130231279Abstract: The disclosure provides a method for enhancing memory of a subject, lowering blood glucose levels in a subject, and treating schizophrenia, the methods comprise intranasally administering to the subject an amount of a oxytocin peptide or analogue thereof having a beneficial effect.Type: ApplicationFiled: July 30, 2011Publication date: September 5, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: David Feifel
-
Patent number: 8524253Abstract: This invention is directed to a bone regeneration device including fascia and demineralized bone matrix mixed at a temperature not exceeding about 40° C. and lyophilized into the bone regeneration device, methods of preparing such a bone regeneration device and methods of treating bone defects using such a bone regeneration device.Type: GrantFiled: November 25, 2008Date of Patent: September 3, 2013Assignee: Warsaw Orthopedic, Inc.Inventors: Keith Matthew Kinnane, Susan J. Drapeau
-
Publication number: 20130225488Abstract: The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-1 receptor agonistic activity.Type: ApplicationFiled: September 28, 2007Publication date: August 29, 2013Inventors: Rajesh H. Bahekar, Braj Bhushan Lohray, Vidya Bhushan Lohray, Mukul R. Jain, Kaushik M. Banerjee, Pankaj Ramanbhai Patel
-
Patent number: 8518892Abstract: The expression of a mRNA encoding a putative 76 amino acid, secreted protein (“Enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Enho1 mRNA in two mouse models of obesity, KK-Ay and Lepob/Lepob mice. Over-expression of Enho1 by adenovirus injection significantly, and reproducibly, reduced fasting triglyceride and cholesterol levels in both models. In addition, transgenic mice strains were made that over express Enho1 protein. Additionally, the expression of a key gene involved in lipogenesis (fatty acid synthase) and FAS protein levels were reduced by ENHO1 adenoviral treatment in Lepob/Lepob mice.Type: GrantFiled: August 2, 2010Date of Patent: August 27, 2013Assignee: Board of Supervisors of Louisiana State University and Agricultural Mechanical CollegeInventors: Andrew A. Butler, James L. Trevaskis
-
Publication number: 20130216504Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.Type: ApplicationFiled: December 21, 2012Publication date: August 22, 2013Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCEInventor: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE
-
Publication number: 20130210703Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.Type: ApplicationFiled: March 15, 2013Publication date: August 15, 2013Applicant: Bristol-Myers Squibb CompanyInventor: Bristol-Myers Squibb Company
-
Publication number: 20130203651Abstract: The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.Type: ApplicationFiled: January 21, 2011Publication date: August 8, 2013Applicant: SANOFIInventors: Mark Sommerfeld, Hans-Ludwig Schaefer, Oliver Boscheinen, Paul Habermann, Ercole Rao, Matthias Dreyer
-
Publication number: 20130196898Abstract: The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.Type: ApplicationFiled: November 26, 2010Publication date: August 1, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Klaus Dugi, Eva Ulrike Graefe-Mody, Michael Mark, Hans-Juergen Woerle, Heike Zimdahl-Gelling
-
Publication number: 20130196905Abstract: Methods for improving the health of a female human or non-human animal are disclosed. The methods include the step of administering to the animal compositions including an effective amount of glycomacropeptide (GMP) for effectuating the methods. Specifically, the methods can be used to increase the rate of fat metabolism or fat oxidation, decrease percentage of body fat, increase the rate of bone mineralization, increase bone mineral content, increase bone mineral density, and/or increase bone strength in the animal. GMP-containing compositions can be used according to the disclosed methods to treat obesity and related metabolic conditions, or to treat or prevent osteoporosis, osteopenia, and other conditions related to loss of bone mineral content or bone strength.Type: ApplicationFiled: January 31, 2013Publication date: August 1, 2013Applicant: Wisconsin Alumni Research FoundationInventor: Wisconsin Alumni Research Foundation
-
Publication number: 20130190226Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.Type: ApplicationFiled: June 30, 2011Publication date: July 25, 2013Inventors: Samuel Wright, Martin Imboden, Reinhard Bolli, Marcel Waelchli
-
Publication number: 20130190232Abstract: Analogues of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD).Type: ApplicationFiled: July 18, 2011Publication date: July 25, 2013Applicant: NOVO NORDISK A/SInventors: Tina Moeller Tagmose, Patrick William Garibay, Xujia Zhang, Henning Thoegersen, Peter Kresten Nielsen, Birgitte Andersen, Jishu Wang, Kristian Sass Bak-Jensen, Helle Fabricius Woeldike
-
Publication number: 20130172250Abstract: Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microshperes encapsulating the exenatide.Type: ApplicationFiled: February 22, 2013Publication date: July 4, 2013Applicants: Astrazeneca Pharmaceuticals LP, Amylin Pharmaceuticals, LLCInventors: Amylin Pharmaceuticals, LLC, Astrazeneca Pharmaceuticals LP
-
Publication number: 20130172233Abstract: An extract for preventing or treating thrombotic diseases, particularly, an extract of at least one of leeches and earthworms having a molecular weight of no more than 5,800 daltons is provided, wherein the extract includes 15% to 38% amino acid, 40% to 60% saccharide and 0.3% to 1% hypoxanthine. Processes for preparation, pharmaceutical compositions and uses thereof are also provided. Compared to conventional arts, the extract has safety greatly improved and drug actions maintained and even improved.Type: ApplicationFiled: June 17, 2012Publication date: July 4, 2013Inventor: Zhenguo Li
-
Patent number: 8476221Abstract: Embodiments described herein are directed to methods for the treatment and control of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae that are associated with these diseases, including atherosclerosis and non-insulin dependent diabetes. In addition, embodiments are directed to methods of treating coronary heart disease and metabolic syndrome. Embodiments are also directed to neurotensin analogs. In embodiments, the neurotensin analogs may be capable of binding to neurotensin receptors and, upon binding, may modulate the levels of lipids in subjects.Type: GrantFiled: March 19, 2012Date of Patent: July 2, 2013Assignee: Halimed Pharmaceuticals, Inc.Inventors: Gautam S. Ghatnekar, Justin Brower
-
Publication number: 20130157935Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: June 23, 2011Publication date: June 20, 2013Applicant: Zealand Pharma A/SInventors: Eddi Meier, Ditte Riber, Jens Rosengren Daugaard, Marie Skovgaard
-
Patent number: 8460659Abstract: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.Type: GrantFiled: September 12, 2011Date of Patent: June 11, 2013Assignee: Janssen Biotech, Inc.Inventors: Mark Cunningham, Yiqing Feng, Katharine Heeringa, Jinquan Luo, Robert Rauchenberger, Mark Rutz, Lani San Mateo, Robert Sarisky, Vedrana Stojanovic-Susulic, Raymond Sweet, Fang Teng, Alexey Teplyakov, Linda Wu, Sheng-Jiun Wu
-
Publication number: 20130143797Abstract: The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-?2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as ? adrenergin receptor agonists, ? adrenergin receptor antagonists, and/or glycemic control agents.Type: ApplicationFiled: June 27, 2011Publication date: June 6, 2013Inventors: Michael J. Tisdale, Steven Russell
-
Patent number: 8455017Abstract: An active substance of medication or health product for hyperlipidemia and hypercholesterolemia comprises djulis, and which can effectively inhibit the absorption of cholesterol, advance the metabolism of cholesterol, promote the anti-oxidation and decrease the accumulation of oxidized low-density lipoprotein-cholesterol in vessel walls of organisms.Type: GrantFiled: April 15, 2011Date of Patent: June 4, 2013Assignee: National Pingtung University of Science & TechnologyInventors: Pi-Jen Tsai, Hso-Chi Chaung
-
Publication number: 20130137629Abstract: Various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis can be treated with a compound selected from an incretin mimetic and a dipeptidyl peptidase IV inhibitor in combination with a Compound of Formula I or a pharmaceutically acceptable salt thereof Three of R1, R2, R3, R4 and R5 are hydrogen and the remainder are independently selected from the group consisting of hydrogen, halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; and m is 0, 2 or 4. R6 is hydrogen, O or hydroxy, and X is —OR7, wherein R7 is hydrogen or alkyl having from 1 to 3 carbon atoms; or R6 is hydrogen, and X is —NR8R9, wherein R8 is hydrogen or hydroxy and R9 is hydrogen, methyl or ethyl. When X is —NR8R9, hydroxy none of R1, R2, R3, R4 and R5 is hydroxy.Type: ApplicationFiled: January 24, 2013Publication date: May 30, 2013Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventor: WELLSTAT THERAPEUTICS CORPORATION
-
Publication number: 20130137628Abstract: An isolated oxidation-resistant ApoA1 variant dimer includes a first oxidation-resistant ApoA1 variant polypeptide monomer and a second oxidation-resistant ApoA1 variant polypeptide monomer, wherein at least one of the first and the second monomers comprises at least one amino acid substitution of a tryptophan residue for an oxidation resistant amino acid, or a functional fragment or variant thereof. Methods for treating a disease or disorder comprises administering to a subject in need thereof, a therapeutically effective amount of an isolated oxidation-resistant ApoA1 variant dimer, an oxidation-resistant ApoA1 variant monomer, an oxidation-resistant ApoA1 monomer-lipid complex, a lipid complexed oxidation-resistant ApoA1 variant monomer, a lipid complexed oxidation-resistant ApoA1 variant dimer, or combinations thereof to the subject to enhance cholesterol efflux activity in the presence of an oxidant.Type: ApplicationFiled: May 11, 2011Publication date: May 30, 2013Applicant: ESPERION THERAPEUTICS, INC.Inventors: Roger S. Newton, Rai Ajit K. Srivastava, Timothy R. Hurley, Clay Cramer, Sergey V. Filippov, Stephen L. Pinkosky
-
Publication number: 20130123173Abstract: The present invention provides non-naturally occurring polypeptides that are oxidation resistant and have cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABACI that parallels that of full-length apolipoproteins. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia and inflammation; and diagnostic methods employing the peptides to evaluated cholesterol efflux activity.Type: ApplicationFiled: April 28, 2011Publication date: May 16, 2013Applicant: The Regents of the University of CaliforniaInventors: John K. Bielicki, Jan Johansson
-
Patent number: 8431532Abstract: Methods of treatment using Fzd8 extracellular domains (ECDs), Fzd8 ECD fusion molecules, and/or antibodies that bind Fzd8 are provided. Such methods include, but are not limited to, methods of treating obesity and obesity-related conditions. Fzd8 ECDs and Fzd8 ECD fusion molecules are also provided. Polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules are provided. Methods of making and using Fzd8 ECDs, Fzd8 ECD fusion molecules, and antibodies that bind Fzd8 are also provided.Type: GrantFiled: June 27, 2011Date of Patent: April 30, 2013Assignee: Five Prime Therepeutics, Inc.Inventors: Thomas Brennan, Ernestine Lee, Steven Smith
-
Patent number: 8426363Abstract: The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.Type: GrantFiled: September 2, 2011Date of Patent: April 23, 2013Assignees: Rinat Neuroscience Corp., Pfizer Inc.Inventors: Hong Liang, Yasmina Noubia Abdiche, Javier Fernando Chaparro Riggers, Bruce Charles Gomes, Julie Jia Li Hawkins, Jaume Pons, Yuli Wang
-
Publication number: 20130089545Abstract: The invention provides a peptide comprising the amino acid sequence given below, together with uses of the peptide and methods associated therewith. The peptide finds particular use as an appetite suppressant and in the treatment of obesity.Type: ApplicationFiled: September 22, 2011Publication date: April 11, 2013Inventor: Stephen Robert Bloom
-
Publication number: 20130085098Abstract: This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.Type: ApplicationFiled: September 25, 2012Publication date: April 4, 2013Applicant: ELI LILLY AND COMPANYInventor: ELI LILLY AND COMPANY